Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 26, 2022

Nivolumab Plus Ibrutinib in Patients With DLBCL Richter Transformation of CLL

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL
Blood Adv 2022 Oct 26;[EPub Ahead of Print], N Jain, J Senapati, B Thakral, A Ferrajoli, PA Thompson, JA Burger, S Basu, TM Kadia, NG Daver, G Borthakur, M Konopleva, N Pemmaraju, EM Parry, CJ Wu, JD Khoury, CE Bueso-Ramos, N Garg, X Wang, W Lopez, A Ayala, SM O'Brien, HM Kantarjian, MJ Keating, JP Allison, P Sharma, WG Wierda

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading